A Study of RO5045337 in Patients With Solid Tumors
This open-label, randomized, cross-over study will evaluate the effect of food on the pharmacokinetics of single oral doses of RO5045337 in patients with solid tumors. The anticipated time on study treatment is 3 weeks.
Neoplasms
DRUG: RO5045337
Examination of potential food-effect on pharmacokinetics of RO5045337, 3 weeks|Evaluation of relative bioavailability of RO5045337, 3 weeks
Evaluation of safety and tolerability of RO5045337, 3 weeks|Evaluation of pharmacodynamics and biomarkers, 3 weeks
This open-label, randomized, cross-over study will evaluate the effect of food on the pharmacokinetics of single oral doses of RO5045337 in patients with solid tumors. The anticipated time on study treatment is 3 weeks.